Life Tech (LIFE) Acquires Cancer Bioinformatics Company Compendia Bioscience

Life Technologies Corporation (Nasdaq: LIFE) announced the acquisition of Compendia Bioscience, a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. Its deep oncology expertise and high-value, proprietary assets enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR and proteome analysis.

Compendia's existing business, which will continue under the leadership of its current management team, adds an established base of pharmaceutical industry customers for Life Technologies' platforms. Compendia's oncology data is widely utilized by leading pharmaceutical companies in their drug development work and will extend Life's abilities to both develop its own tests and to partner with pharmaceutical companies in companion diagnostic development.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ethos to Present at the Goldman Sachs Communacopia + Technology Conference
• ScanSource to acquire MicroAge for $220.5 million in cash
• Treasure Global sells shares in two deals worth $6.6M total